Introduction. Orally administered angiotensin receptor antagonists administered after baremetal stent implantation and even after drugeluting stent implantation seem to lower in-stent restenosis rates. Whether valsartan-eluting stents are similarly effective was tested here in a first-in-man trial. Materials and methods. The efficacy of a polymer-free drug-eluting stent coated with 300 mcg valsartan was compared to a coating with a 2% rapamycin solution in small (≤ 2.5 mm) coronary vessels with and without oral valsartan on the basis of the YUKON Choice stent system (Translumina GmbH, Hechingen, Germany). Fifteen patients (eight males, mean age 64.4±7.7 years) were treated with YUKON Choice valsartan-eluting stents and 30 patients (24 males, mean age 65.7±8.4 years) received YUKON Choice rapamycin-eluting stents. Clopidogrel was given for six months in all patients. Results. Within the first 30 days, no adverse events occurred in either group. Binary in-stent restenosis rate was 30.8% (four in 13 angiographic controls) in the valsartan-eluting stent group and 35.0% (eight in 20 angiographic controls) in the rapamycin-eluting YUKON Choice stent group. Mean late lumen loss was 0.78±0.53 mm and 0.79±0.58 mm, respectively. Target lesion and target vessel revascularisation rate was 26.6% and 25.0%, respectively. No restenoses in rapamycin-eluting YUKON Choice stents appeared in 12 patients with adjunct oral valsartan administration. Conclusions. If polymer-free YUKON Choice stents are used in small vessels, valsartan-eluting stents show an identical efficacy as rapamycinloaded stents. In patients with rapamycineluting YUKON Choice stents it seems that the efficacy can be increased by oral valsartan administration.
Introduction
Rapamycin and paclitaxel drug-eluting stents are effective in reducing restenosis even in complex coronary interventions and patients with high major adverse cardiac events (MACE) rates. 1, 2 Nevertheless, the use of polymers and cytotoxic agents leads to a delay of endothelial healing 3 and consecutive late and very late stent thrombosis with an annual increase of about 0.6% after termination of dual antiplatelet therapy. 4 Experiences with drug-eluting stents in small vessels seem to favour CYPHER sirolimus-eluting stents. [5] [6] [7] [8] According to the Basel Stent Kosten Effektivitäts Trial (BASKET), cost effectiveness for drug-eluting stents is present especially for small coronary vessels. 9 Oral administration of angiotensin II type 1 receptor antagonist valsartan in a dosage of 80 mg after bare-metal stent implantation in type B2/C lesions can reduce in-stent restenosis in comparison to placebo 10 and angiotensinconverting enzyme inhibitors. 11 This effect can be even increased by high-dose (160-320 mg) valsartan according to recent data. 12 First experiences in a rabbit model have been made with valsartan-eluting polymer-based stents 13 in a dosage of 300 mcg per square centimetre strut surface with significantly larger luminal area and less neointimal hyperplasia possibly due to expression of angiotensin II type 2 receptor activity not only in the adventitia but also in the intima of the vessel wall under valsartan loading.
The purpose of the first-in-man study was to test the hypothesis that active valsartan coating on the surface of the YUKON Choice stent (Translumina GmbH, Hechingen, Germany) is a safe procedure and can reduce in-stent restenosis in small coronary vessels in comparison to polymer-free rapamycin-eluting stents with and without oral valsartan administration.
First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free rapamycin (2%)-eluting stents 
Materials and methods
Forty-five patients (32 males, mean age 65.1±8.1 years) with a single target lesion in small vessels (diameter ≤ 2.5 mm) were included in a prospective randomised single-centre trial using the YUKON Choice polymer-free stent design in order to use different drug coatings: a valsartan solution as a first-in-man experience and a 2% rapamycin solution already established in the treatment of human coronary artery disease. The first-in-man use of valsartan-eluting stents in 15 patients with planned control angiography after six months was approved by the local Ethics Committee and patients were included after informed written consent. YUKON Choice stents were loaded in 15 cases with a mean dosage of 300 mcg per square centimetre strut surface area in undilated stents with a length of 16 mm and with approximately 480 mcg rapamycin per square centimetre stent surface area 14 in 30 consecutive patients with comparable demographic, clinical and angiographic features. In 15 cases with rapamycin-eluting YUKON Choice stents, oral valsartan was added in a dosage between 160 and 320 mg per day.
Inclusion criteria were an age of more than 18 years, symptoms of stable or unstable angina and a haemodynamically significant coronary lesion of more than 70% with a maximum length of 24 mm and a maximum diameter of 2.5 mm.
Exclusion criteria were coronary diameters of more than 2.5 mm, chronic total occlusion, left main stenosis, in-stent restenosis, bypass stenosis, ostial lesion, highly calcified lesions, restenosis after percutanuous transluminal coronary angioplasty, multi-vessel disease with planned multi-stage percutanuous coronary intervention (PCI), bifurcational lesion with a diameter of the side branch of more than 2.0 mm, visible intracoronary thrombi, known allergy to heparin, clopidogrel, aspirin, contrast medium or other agents, acute myocardial infarction within the last 48 hours, pregnancy, severe platelet dysfunction, severe bleeding risk, liver dysfunction and lack of patient compliance.
All patients received 5,000 IU heparin intravenously in the catheter laboratory. Clopidogrel was given directly after stent implantation at a loading dose of 300 mg and a continuous dosage of 75 mg for six months. Oral aspirin was continued at a dosage of 100 mg.
Follow-up angiograms were analysed with regard to the following parameters: reference diameter of the target vessel in mm, minimal lumen diameter in mm, grade of stenosis in percent and late lumen loss in mm. These parameters were analysed within the stent and in addition at 5 mm proximal and distal stent edges.
Primary end-point of the trial was a combined MACE rate within the first 30 days including cardiac death, myocardial infarction, stent thrombosis and target lesion revascularisation.
Secondary end-points were binary angiographic restenosis rate, target lesion revascularisation, target vessel revascularisation, cardiac death, late lumen loss and a combined end-point of cardiac death, myocardial infarction, stent thrombosis and target lesion revascularisation within the next six months.
Unexpected adverse events were documented.
Categorical data were analysed by x 2 -test and continuous variables documented as mean values with standard deviation (±SD) by student t-test, both with a p value of < 0.05 for significance.
Results
YUKON Choice stents with a length between 16 and 24 mm and a diameter between 2.0 and 2.5 mm were implanted successfully in all 45 patients with a thrombolysis in myocardial infarction III flow post intervention without evidence of coronary thrombi. In 44 patients, single stents were used. Only in one female patient in the valsartaneluting stent group was the implantation of two overlapping stents necessary in order to cover a progressive dissection. Stent implantation with an implantation pressure between 10 and 12 bar was performed in all cases after pre-dilatation of the lesion. Post-dilatation of the stent was necessary in 12 cases (27%). Within the first 30 days, no major adverse cardiac or non-cardiac events occurred.
Follow-up angiography was done in 13 out of 15 patients (87%) with valsartan-eluting stents and in 20 patients (67%) with rapamycin-eluting YUKON Choice stents. Twelve of these 20 patients had oral valsartan medication in a dosage between 160 and 320 mg per day. One female patient died within six months because of a previously undetected neoplasm. Eleven patients refused control angiography because of the absence of cardiac symptoms.
Binary angiographic restenosis of ≥ 50% of the target lesion was found in four out of 13 patients (30.8%) with valsartan-eluting stents. Target vessel and target lesion revascularisation in cases of recurrent angina and/or proven ischaemia was carried out in all cases with concurrent angiography control. Mean late lumen loss in the treated coronary segments was 0.78±0.53 mm.
In the group of rapamycin (2%)-eluting YUKON Choice stents, binary angiographic restenosis of ≥ 50% was found in eight out of 20 patients (35%) who had no adjunct oral valsartan treatment. Target vessel revascularisation (TVR) and target lesion revascularisation (TLR) rates were 25% due to chronic occlusions in three cases without symptom and without proven ischaemia after six months.
Cardiac death, myocardial infarction or stent thrombosis did not occur in any patients within the clinical follow-up of six months (table 3) . 
Discussion
Currently-used first-generation drug-eluting stents can effectively reduce in-stent restenosis and TVR and TLR rates even in complex procedures. There is ongoing discussion about the safety of drugeluting stents with regard to late (within 12 months) or very late (after more than 12 months) stent thrombosis possibly induced by polymer coating and delay in endothelial healing due to rapamycin and paclitaxel. Furthermore, results with drug-eluting stents in small vessels favour CYPHER sirolimus-eluting stents containing 140 mcg of sirolimus per square centimetre of stent surface area, whereas paclitaxel-coating results in higher late lumen loss, restenosis rate and MACE rate. [5] [6] [7] [8] In order to develop new stent designs, polymer-free stents such as the YUKON Choice stent, with the possibility of using new agents, have gained increasing interest.
The angiotensin II type 1 receptor antagonist valsartan seems to reduce in-stent restenosis after bare-metal stent implantation even in type B2/C lesions when administered orally at a dosage of 80 mg. 10, 11 Recent data suggest that the effect of restenosis prevention is increased if higher dosage (160-320 mg) is used. 12 However, according to some small studies on candesartan [15] [16] [17] and losartan, 18 even with higher doses prevention of in-stent restenosis is not possible. Early data exist which show that telmisartan is also able to reduce in-stent restenosis after bare-metal stent 19 and even after drug-eluting stent implantation. 20 The theoretical effects of angiotensin II type 1 receptor antagonists may be due to anti-inflammatory action, 21 reduction of platelet activity, 21 indirect activation of the angiotensin II type 2 receptor activity 22 thus reducing RhoA and RhoA kinase activity 23 as a risk factor of in-stent restenosis, 24 reduction in the number of smooth muscle progenitor cells and beneficial effects on endothelial progenitor cells 25 and long-lasting reduction of plasma aldosterone levels 26 which has been identified as an additional risk factor of in-stent restenosis. 27 The results of the present trial imply that polymerfree valsartan at a dosage of 300 mcg per square centimetre strut surface area and coated with a 2% rapamycin solution containing nearly 480 mcg per square centimetre produce nearly identical results in small vessels with regard to restenosis rate and late lumen loss. Although the number of patients included is rather small, it seems that the results of polymer-free rapamycin-eluting YUKON Choice stents can be improved by oral valsartan administration. Although the results with regard to in-stent restenosis rate and late lumen loss may be far beyond what can be achieved by CYPHER sirolimuseluting stents in this special indication, [5] [6] [7] [8] this pilot study with valsartan-eluting stents represents the first attempt to gain experience with regard to feasibility and safety with direct stent loading of the angiotensin II type 1 receptor antagonist valsartan. Modifications of dosage and stent design have to be considered.
According to the experiences of using oral valsartan for preventing restenosis after bare-metal stent implantation, it is known that the effect of valsartan is clearly dose-dependent. 12 Before starting this pilot study with valsartan-eluting stents, the ability of loading valsartan on the surface of YUKON Choice stents was tested in an in vitro model. Due to the physical properties of valsartan in ethanol solution -valsartan is nearly completely insoluble in water but highly soluble in fat -the possibility of increasing the dosage on the YUKON Choice stent system is limited and dosage is reduced after stent expansion. These experimental observations were the basis for the dosage chosen in our human pilot study, but lead to the question whether a polymer-free stent design is the ideal coating system for valsartan.
The beneficial effects of adjunct oral valsartan with rapamycin-eluting YUKON Choice stents lead to the question whether combining valsartan and other agents such as rapamycin on the stent surface improves outcome. A similar attempt has been made with a combination of rapamycin and estradiol without differences in comparison to pure rapamycin coating in the short-term followup, 28 but long-term results are awaited with regard to late stent thrombosis.
The results of the present trial do not demonstrate a definite role for valsartan stent coating in order to reduce restenosis in small coronary vessels. Optimisation of valsartan dosage and release kinetics seems to be necessary. Nevertheless, from a theoretical point of view continued interest in stent coating with angiotensin II type 1 receptor antagonists exists as endothelial dysfunction by stent implantation may be diminished thus perhaps overcoming the clinical problem of late and very late stent thrombosis.
